Curative Ventures

About The Fund

Curative Ventures is a venture capital firm that specializes in investments in the biotech industry. Founded in 2010 and based in Dallas, Texas, Curative Ventures positions itself as both a capital and talent partner for category-defining biotech companies focused on developing new therapies aimed at dramatically improving patient outcomes. The firm operates with an investment philosophy centered around supporting innovative biotech enterprises that push the boundaries of medical science to create significant advancements in patient care. With their targeted investment approach, Curative Ventures is dedicated to nurturing the growth of companies that possess the potential to lead breakthroughs in various therapeutic areas. Among their portfolio investments are companies like InstilBio, CoStim, iTeos Therapeutics, TCR2, and Peloton Therapeutics, reflecting their engagement with cutting-edge biotech research and development. Their recent activities also underline their strategic involvement in the sector, as evidenced by press releases detailing collaborations, initial public offerings, and acquisitions, such as licensing agreements with Instil Bio and ImmuneOnco, the IPO of InstilBio, the acquisition of Exonics by Vertex, Merck's purchase of Peloton Therapeutics, and TCR2 Therapeutics' IPO. Curative Ventures showcases a significant commitment to transformative biotech innovations through consistent support and investment, with an emphasis on singular scientific ventures that can change the course of treatment for various conditions. They operate with a minimum and maximum investment size of $74,720,000, indicating a focused strategy on sizeable, potentially high-impact investments within the biotech space.